
    
      The duration of the study for each patient is planned between 4 and 7 weeks including a
      screening period (25 to 30 days), 3 treatment periods 1-7 days apart, each period lasting
      only one day (Day 1) and an end-of-study visit between 1 to 7 days after the last dose
      administration.
    
  